BTIG analysts said today that MiniMed, the Medtronic (NYSE:MDT) diabetes business, has some significant pipeline updates.
Our sister site, Drug Delivery Business News, reports today that Marie Thibault, Sam Eiber and Alexandra Pang shared notes from their meeting with Que Dallara, soon-to-be CEO of the to-be separated Diabetes unit, at the American Diabetes Association’s 85th Scientific Sessions in Chicago.
Among those updates, the company expects to submit a new automated insulin delivery system, the MiniMed Flex (8 series) pump, to the FDA by the end of the fiscal year. (Medtronic’s fiscal year ends in April, meaning the submission could come by spring 2026.)
It also continues to prepare for a label expansion to type 2 diabetes for the currently available MiniMed 780G. Finally, analysts say they received a look at the company’s in-development MiniMed Fit patch pump.
Get the full story at our sister site, Drug Delivery Business News.
